Antihypertensives associated with lower dialysis risk for patients with advanced CKD

Patients with stable hypertension and the most advanced stage of chronic kidney disease (CKD) before dialysis appeared to have a lower risk for long-term dialysis or death if they were treated with the antihypertensive drugs known as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), according to a study published by JAMA Internal Medicine.

An ACEI or ARB is known to delay the progression of CKD in with and without diabetes, particularly in those patients with mild to moderate . But most large clinical trials of ACEI/ARB exclude patients with the most of CKD predialysis, perhaps out of concern that the drugs can cause renal failure and the need for dialysis, so it remains unclear whether that therapy is effective in patients with advanced CKD, according to the study background.

Researchers in Taiwan examined the association between ACEI/ARB use and the risk of long-term dialysis and death in a nationwide group of 28,497 patients in a study by Ta-Wei Hsu, M.D., of the National Yang-Ming University Hospital, and colleagues. The patients had the most advanced predialysis stage of CKD, hypertension and anemia.

During a median follow-up of seven months, 20,152 patients (70.7 percent) required long-term dialysis and 5,696 (20 percent) died before progressing to ESRD (end-stage ). Study findings indicate that treatment with ACEIs/ARBs in patients with stable and advanced CKD was associated with a lower risk for long-term dialysis or death by 6 percent.

"In conclusion, our findings expand the existing knowledge in the field and provide clinicians with new information," the authors conclude.

In a related commentary, Meyeon Park, M.D., M.A.S., and Chi-yuan Hsu, M.D., M.Sc., of the University of California, San Francisco, write: "In the treatment of patients with advanced (CKD) … a paramount goal is preventing or retarding progression to end-stage renal disease and the requirement of dialysis."

"However, the use of ACEIs or ARBs in advanced CKD remains uncertain. This important clinical question is the subject of a new study by Hsu and colleagues," the authors continue. "Overall, the study by Hsu and colleagues makes an important contribution to the literature."

More information: JAMA Intern Med. Published online December 16, 2013. DOI: 10.1001/jamainternmed.2013.12700
JAMA Intern Med. Published online December 16, 2013. DOI: 10.1001/jamainternmed.2013.12176

add to favorites email to friend print save as pdf

Related Stories

Wider statin use recommended for chronic kidney disease

Dec 10, 2013

(HealthDay)—New guidelines for lipid management in chronic kidney disease (CKD) recommend wider statin use, according to a clinical practice guideline published online Dec. 10 in the Annals of Internal Me ...

Recommended for you

An approach to fighting the Ebola virus

24 minutes ago

Terrible suffering in Western Africa has refocused the world's attention on Ebola viruses, for which there is no vaccine or cure. The viruses are masters of their attack, but researchers are working hard to fight them, said ...

UN Ebola pointman to visit west Africa

2 hours ago

The UN's new pointman on Ebola was due to arrive in west Africa on Thursday for a visit aimed at shoring up health services in the region where at least 1,350 lives have been lost to the virus.

Two Americans with Ebola leave hospital (Update)

4 hours ago

Two American missionaries who fell ill with the dangerous Ebola virus while working in Liberia have recovered and have been released from an Atlanta hospital, doctors said Thursday.

Leprosy: Myanmar struggles with ancient scourge

8 hours ago

High in the hills of Myanmar's war-torn borderlands, a clutch of new leprosy cases among communities virtually cut off from medical help is a sign that the country's battle with the ancient disease is far from over.

User comments